Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
“The randomised control trial (RCT) – the ‘gold standard’ for clinical evidence.
If that is so, why is all evidence not gathered in such a manner.
For those in research, the answer is evident but doctors and scientists forget that the complexities of the nuts and bolts of a quality trial are not common knowledge of our patients.
Not all questions can be answered with an RCT, not to mention the cost in setting one up.
Trials with mild or moderate methodological failing or negative results may not even get published, with the hard work never known outside the investigating team.
For anyone who wanted a quick overview of RCTs but was a little afraid or embarrassed to ask, here is a quick video for you.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat